Aiming at international demand, biopharmaceutical industry seeks collaborative development

　　Our reporter Cui Caifeng reported that "single-handedness for every biomedicine enterprises, and even every high-tech zone, is not a good development model, through cross-industry, cross-regional cooperation, the formation of collaborative development mechanism is the best way "Shijiazhuang Yiling Pharmaceuticals (002603, stock bar) Co , Ltd head Yang Chao's words said a lot of biomedicine industry the voice of enterprises at present, the biomedical industry with high input, high risk, high value added value and high return is becoming the leading force in the world economy, and China is also expected to become the world's second largest pharmaceutical market How to promote the rapid development of China's biopharmaceutical industry, so that it in the international competition to form a voice has become the industry has to consider the issue synergy development theory, because of advocating mutual cooperation, mutual benefit and win-win situation, has been determined by many countries and regions in the world to achieve sustainable social development, but also the current direction of China's biopharmaceutical industry efforts collaborative development of the demand Innovative industrial cluster is an effective organization form to enhance the competitiveness of regional leading industries, through industrial clusters to achieve industrial transformation and upgrading, improve regional competitiveness is the international common practice In 2011, the Ministry of Science and Technology, focusing on the National High-tech Zone, initiated the implementation of the "Innovative Industrial Cluster Construction Project" and selected 15 national high-tech zones for bio-ferrous innovative industrial clusters to enter into cultivation and pilot construction in five strategic emerging industries in 34 provinces, regions and cities in recent years, each cluster has done some public service platform construction, public resources sharing and other aspects of their own work, promote the development of the cluster, and developed some innovative, international, industrialization products, but each cluster has different advantages and shortcomings, clusters and clusters have not formed a good coordination of development mechanism, most biopharmaceutical industry clusters are still in a single situation, the development of enterprises in the cluster is very difficult Wang Lin, assistant general manager of Liaoning Cape Medical Systems Co., Ltd in , said that the national medical device MRI and X-ray machine are the main products of Cape Medical, these products related to the core components are the company's own research and development, but in each research and development process will encounter many problems The first is the shortage of talent, in China's northeast region, the annual loss of up to 2 million talent, the shortage of talent resources has become a major constraint on the development of regional pharmaceutical enterprises an important factor Due to geographical conditions and other factors, the introduction of talent in the Northeast is very difficult compared with other regions, and even if it is introduced, how to retain is not a small challenge Second, financial difficulties, enterprise research and development needs a large amount of financial support, which is a new enterprise, the pressure is not small Although the park through a variety of channels to help enterprises to solve this problem, but many have not been able to achieve Again, The sale, Cape Medical in 2012 to obtain the relevant product sales license, in 2014 sold a product to Malaysia, this year sold a product to Iran, three years time only to open the Central Asian market, the Western market simply can not enter "This is a real problem for our business," And these problems exist not only in Cape Healthcare, but in most businesses Wang Lin said, how to build a larger platform, on a larger platform everyone sings together, exchanges and cooperation, get more support and help, contact upstream and downstream and related enterprises, this is The most hope of Cape Medical problems large platform to promote synergy contact upstream and downstream and related enterprises, promote cross-regional exchanges and cooperation between the industry, for this collaborative development mechanism, Shijiazhuang Stone Pharmaceutical Group Co., Ltd research and development manager Du Yadong has a deep understanding According to him, Stone Pharmaceutical Group has a product called butyl benzene, is now very good sales, is a class of new drugs in China's first breakthrough 1 billion yuan of single products He said that the success of butyl benzene in fact benefit from the combination of production and research, butyl benzene is the initial stage of the development of products in Concord, stone medicine put it into a market-oriented operation, fully demonstrated that the combined force of production, research and research is very large Du Yadong said that stone pharmaceutical group last year under the leadership of Shijiazhuang High-tech District, the establishment of China's pharmaceutical auxiliary pharmaceutical preparationindustry alliance, after a year of operation, the alliance for the development of the industry has played a very good synergy, this synergy can contribute to the future development of enterprises, a comprehensive, comprehensive, open technology development system Only by relying on this system, the future development of enterprises will continue to be good, innovation can be fundamental changes is to see the great effect of collaborative development, the Ministry of Science and Technology Torch Center in the construction of innovative industrial clusters repeatedly stressed the establishment of collaborative development mechanism, and recently organized the establishment of a national high-tech zone biomedical innovation industry cluster conference system Around the overall competitiveness of the alliance members, the formation of cross-regional exchanges, multi-platform sharing, deep-level cooperation of the innovation and collaboration community Through the exchange of experience, problem diagnosis and strategic discussion, we will try to guide the high-tech areas to highlight the characteristics in the sub-sector of the biopharmaceutical industry, focus on the advantages, gather resources, and form industrial brands, cluster brands and urban brands By guiding the synergy of various resources to the cluster industry chain, we strive to form the biopharmaceutical industry in the high-tech zones in the international competition to form "technology discourse, product pricing power, market development right" ", the establishment of such a platform for the entire biopharmaceutical industry is a big advantage, but the key still depends on how to implement, I hope this platform can really for the cluster, for enterprises to solve practical problems "For the national high-tech zone bio-medicine innovative industrial cluster conference system, biopharmaceutical enterprises give unanimous appreciation and expectations strive for industry voice as an advance goal" for the needs of cluster members
set up a shared information exchange platform, through the market way to provide technical services, financial services, talent and operations management services Different provinces can really build a platform for each other in terms of technology and talent, and play a complementary role "How to establish a cooperative development mechanism for the innovative industrial cluster of biomedicine in the national high-tech zone, Wang Aifang, high-tech director of Qinghai Provincial Science and Technology Department, suggested Liu Feng, technical manager of Liaoning Medi Biotech Co., Ltd., said: "Small and medium-sized enterprises to develop a product, from research and development to final production, and finally get a variety of approvals to list is a very long process, through the National High-tech Zone Biopharmaceutical Innovation Industry Cluster Conference System, this platform, can establish close links with government departments, in the process of product approval, timely communication, so that the product development cycle and the process of obtaining approval, so that the product can be timely to recover costs." "
" from the positioning point of view, the national high-tech zone biopharmaceutical innovative industrial cluster conference system should eventually promote China's biopharmaceutical industry in the international competition to form a "technological discourse, product pricing power, market development rights", I think in this process, we must first strive for the right to speak at the promotion level of national policy "Guangdong Guanxuan Biological (300238, stock bar) Technology Co., Ltd Guanqi Science and Technology Park, the relevant person in charge of the project from a policy point of view, the future of the national high-tech zone bio-medicine innovative industrial cluster collaborative development mechanism to promote the work The person in charge said that for enterprises, registration approval, product research and development and many other aspects of difficulties, hope that through this platform, the enterprise reflects the problems submitted to the national level, in order to focus on solving the problems of the entire biopharmaceutical industry Even some norms and standards can be implemented through this platform He believes that this is a more desirable goal than to achieve the first goal in international competition (Responsible Editor: HN666)